PWG
LGND icon

Portside Wealth Group’s Ligand Pharmaceuticals LGND Stock Holding History

Portside Wealth Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Buy
4,810
+1,793
+59% +$422K 0.18% 134
2026
Q1 		$602K Buy
3,017
+184
+6% +$36.4K 0.08% 226
2025
Q4 		$536K Sell
2,833
-1,385
-33% -$266K 0.07% 242
2025
Q3 		$747K Buy
4,218
+725
+21% +$108K 0.1% 203
2025
Q2 		$397K Sell
3,493
-82
-2% -$8.76K 0.06% 283
2025
Q1 		$376K Buy
3,575
+112
+3% +$12.7K 0.06% 279
2024
Q4 		$371K Buy
3,463
+363
+12% +$41K 0.06% 275
2024
Q3 		$310K Buy
3,100
+378
+14% +$38.1K 0.05% 302
2024
Q2 		$229K Buy
+2,722
New +$217K 0.04% 318

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
KPP
Kings Path Partners Sugar Land, Texas $376M AUM 19% 1-Year Est. Return

Portside Wealth Group's LGND Position: Q2 2026 in Review

Portside Wealth Group increased its Ligand Pharmaceuticals (LGND) stake by 59% in Q2 2026, buying an estimated $422K and bringing the position to 4,810 shares worth $1.52M. The position accounts for 0.18% of the portfolio, ranked #134.

Portside Wealth Group first reported a position in LGND in Q2 2024 and has held it in 9 quarters since. 36 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Portside Wealth Group held 4,810 shares of Ligand Pharmaceuticals worth $1.52M as of Q2 2026.
  • Portside Wealth Group bought 1,793 Ligand Pharmaceuticals shares in Q2 2026, an estimated $422K.
  • Ligand Pharmaceuticals made up 0.18% of Portside Wealth Group's portfolio in Q2 2026, its #134 holding.
  • Portside Wealth Group first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 36 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Portside Wealth Group's 13F filing for Q2 2026, filed 14 Jul 2026.